|1.||Dou, Q Ping: 13 articles (05/2014 - 07/2002)|
|2.||Pajonk, Frank: 7 articles (01/2014 - 09/2002)|
|3.||Yang, Huanjie: 6 articles (08/2009 - 05/2006)|
|4.||Chen, Di: 6 articles (05/2009 - 05/2005)|
|5.||Lagadec, Chann: 5 articles (01/2014 - 03/2009)|
|6.||Xu, Jian: 4 articles (07/2014 - 09/2009)|
|7.||Spirina, L V: 4 articles (05/2014 - 07/2010)|
|8.||Kondakova, I V: 4 articles (05/2014 - 07/2010)|
|9.||Vlashi, Erina: 4 articles (01/2014 - 03/2009)|
|10.||McBride, William H: 4 articles (03/2008 - 09/2002)|
02/01/2012 - "We identified the Bcl2 family member MCL1 and several 26S proteasome subunits among the most important and selective multiple myeloma survival genes. "
06/01/2009 - "The 26S proteasome inhibitor, bortezomib, has shown remarkable therapeutic efficacy in multiple myeloma (MM), however, the mechanism by which this compound acts remains unknown. "
01/01/2011 - "Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. "
06/01/2015 - "Previous study demonstrated that bortezomib (BTZ), a 26S proteasome inhibitor used to treat refractory multiple myeloma (MM), exerts deleterious impacts on spermatogenesis in pubertal mice via unknown mechanisms. "
08/01/2010 - "Bortezomib, a potent 26S proteasome inhibitor, is approved for the treatment of multiple myeloma (MM) and clinical trials are under way to evaluate its efficacy in other malignant diseases. "
10/02/2015 - "The best-known activity of E6 is the polyubiquination of the pro-apoptotic tumor suppressor p53, targeting it for degradation by the 26S proteasome. "
09/22/2015 - "The 26S proteasome is a multifaceted target for anti-cancer therapies."
01/01/2015 - "Adhesion-regulating molecule 1 (ADRM1), a receptor located on the 26S proteasome, is upregulated in many solid cancers. "
01/01/2014 - "P28/PSMD10, a regulatory complex of the human 26S proteasome, plays a critical role in tumor genesis. "
01/01/2014 - "Here, we present evidence that the downregulation of the 26S proteasome in CSCs constitutes another level of control by which Musashi-1 promotes signaling through the Notch pathway and maintenance of the stem cell phenotype of this subpopulation of cancer cells. "
|4.||Chronic Disease (Chronic Diseases)
|5.||Prostatic Neoplasms (Prostate Cancer)
06/01/2012 - "We conclude that low 26S proteasome activity identifies a radioresistant prostate cancer cell population. "
07/01/2005 - "Regardless of whether they were irradiated before or after extraction and purification from human prostate cancer PC3 cells, 26S proteasomes remained intact but showed a rapid 30% to 50% dose-independent decrease in their three major enzymatic activities following exposure to 1 to 20 Gy. There was no effect on 20S proteasomes, suggesting that the radiation-sensitive target is located in the 19S cap of the 26S proteasome, rather than in the enzymatically active core. "
06/01/2012 - "In this study we tested if prostate cancer cells are heterogeneous with regard to their intrinsic 26S proteasome activity, which could explain the lack of clinical responses to bortezomib. "
11/01/2003 - "Bortezomib (Velcade; previously called PS-341) is a potent and specific inhibitor of the 26S proteasome that is currently in clinical trials for treatment of various malignancies, including prostate cancer. "
09/15/2002 - "It inhibited 20s and 26s proteasome activity in lysates from LnCaP, DU-145, and PC-3 prostate cancer cells with an IC(50) of 10 micro M and caused the accumulation of an ubiquitin/green fluorescence protein fusion protein in living ECV 304/10 cells. "
|4.||Proteasome Endopeptidase Complex (Proteasome)
|9.||Heat-Shock Proteins (Heat-Shock Protein)
|10.||Type I DNA Topoisomerases (Topoisomerase I)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|5.||Transplantation (Transplant Recipients)